{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T21:50:25Z","timestamp":1790027425714,"version":"4.0.1"},"reference-count":40,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2015,5,6]],"date-time":"2015-05-06T00:00:00Z","timestamp":1430870400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2015,5,6]],"date-time":"2015-05-06T00:00:00Z","timestamp":1430870400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["NIH R01 CA165277 (PI: Aplenc)."],"award-info":[{"award-number":["NIH R01 CA165277 (PI: Aplenc)."]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatr Blood Cancer"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1002\/pbc.25569","type":"journal-article","created":{"date-parts":[[2015,5,6]],"date-time":"2015-05-06T12:46:10Z","timestamp":1430916370000},"page":"1775-1781","source":"Crossref","is-referenced-by-count":25,"title":["Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology Group"],"prefix":"10.1002","volume":"62","author":[{"given":"Kelly D.","family":"Getz","sequence":"first","affiliation":[{"name":"The Children's Hospital of Philadelphia; Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimei","family":"Li","sequence":"additional","affiliation":[{"name":"The Children's Hospital of Philadelphia; Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd A.","family":"Alonzo","sequence":"additional","affiliation":[{"name":"University of Southern California; Los Angeles California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Hall","sequence":"additional","affiliation":[{"name":"Children's Hospital Association; Overland Park Kansas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Gerbing","sequence":"additional","affiliation":[{"name":"Children's Oncology Group; Monrovia California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillian","family":"Sung","sequence":"additional","affiliation":[{"name":"Hospital for Sick Children; Toronto"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Shung","family":"Huang","sequence":"additional","affiliation":[{"name":"The Children's Hospital of Philadelphia; Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Staci","family":"Arnold","sequence":"additional","affiliation":[{"name":"Columbia University Medical Center; New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alix E.","family":"Seif","sequence":"additional","affiliation":[{"name":"The Children's Hospital of Philadelphia; Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara P.","family":"Miller","sequence":"additional","affiliation":[{"name":"The Children's Hospital of Philadelphia; Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rochelle","family":"Bagatell","sequence":"additional","affiliation":[{"name":"The Children's Hospital of Philadelphia; Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T.","family":"Fisher","sequence":"additional","affiliation":[{"name":"The Children's Hospital of Philadelphia; Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Adamson","sequence":"additional","affiliation":[{"name":"The Children's Hospital of Philadelphia; Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Gamis","sequence":"additional","affiliation":[{"name":"Children's Mercy Hospitals and Clinics; Kansas City Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Keren","sequence":"additional","affiliation":[{"name":"The Children's Hospital of Philadelphia; Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Aplenc","sequence":"additional","affiliation":[{"name":"The Children's Hospital of Philadelphia; Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,5,6]]},"reference":[{"key":"10.1002\/pbc.25569-BIB0001|pbc25569-cit-0001","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1200\/JCO.2014.55.3628","article-title":"Gemtuzumab Ozogamicin in children and adolescents with de novo acute myeloid leukemia (AML) improves event-free survival by reducing relapse risk - Results from the randomized Phase III Children's Oncology Group trial, AAML0531l","volume":"32","author":"Gamis","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.25569-BIB0002|pbc25569-cit-0002","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1470-2045(10)70090-5","article-title":"Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: Results of the AML02 multicentre trial","volume":"11","author":"Rubnitz","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1002\/pbc.25569-BIB0003|pbc25569-cit-0003","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1182\/blood-2012-03-416701","article-title":"Nordic Society of Paediatric Haematology and Oncology (NOPHO). Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: Results from NOPHO-AML 2004","volume":"120","author":"Hasle","year":"2012","journal-title":"Blood"},{"key":"10.1002\/pbc.25569-BIB0004|pbc25569-cit-0004","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2013-02-484097","article-title":"Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: Results from Study AML-BFM 2004","volume":"122","author":"Creutzig","year":"2013","journal-title":"Blood"},{"key":"10.1002\/pbc.25569-BIB0005|pbc25569-cit-0005","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/sj.leu.2403958","article-title":"Pediatric acute myeloid leukemia: International progress and future directions","volume":"19","author":"Kaspers","year":"2005","journal-title":"Leukemia"},{"key":"10.1002\/pbc.25569-BIB0006|pbc25569-cit-0006","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2141.2011.08851.x","article-title":"United Kingdom Childhood Leukaemia Working Group and the Dutch Childhood Oncology Group. Results of a randomized trial in children with acute myeloid leukaemia: Medical research council AML12 trial","volume":"155","author":"Gibson","year":"2011","journal-title":"Br J Hematol"},{"key":"10.1002\/pbc.25569-BIB0007|pbc25569-cit-0007","doi-asserted-by":"crossref","first-page":"e273","DOI":"10.1542\/peds.2012-0912","article-title":"Economic evaluation of pediatric cancer treatment: A systematic literature review","volume":"131","author":"Russell","year":"2013","journal-title":"Pediatrics"},{"key":"10.1002\/pbc.25569-BIB0008|pbc25569-cit-0008","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1017\/S0266462307051562","article-title":"Economic evaluations of leukemia: A review of the literature","volume":"23","author":"Kasteng","year":"2007","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1002\/pbc.25569-BIB0009|pbc25569-cit-0009","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.ejca.2004.01.033","article-title":"Economic evaluation of treatments for cancer in childhood","volume":"40","author":"Barr","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1002\/pbc.25569-BIB0010|pbc25569-cit-0010","first-page":"1490","article-title":"Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1002\/pbc.25569-BIB0011|pbc25569-cit-0011","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","article-title":"A phase 3 study of gemtuzumab ozogamicin during induction and post consolidation therapy in younger patients with acute myeloid leukemia","volume":"121","author":"Petersdorf","year":"2013","journal-title":"Blood"},{"key":"10.1002\/pbc.25569-BIB0012|pbc25569-cit-0012","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukemia: A meta-analysis of individual patient data from randomized controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1002\/pbc.25569-BIB0013|pbc25569-cit-0013","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S1470-2045(14)70289-X","article-title":"A new dawn for gemtuzumab ozogamicin?","volume":"15","author":"Kharfan-Dabaja","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1002\/pbc.25569-BIB0014|pbc25569-cit-0014","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/pds.3241","article-title":"Merging of the National Cancer Institute -funded cooperative oncology group data with an administrative data source to develop a more effective platform for clinical trial analysis and comparative effectiveness research: A report from the Children's Oncology Group","volume":"21","author":"Aplenc","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1002\/pbc.25569-BIB0015|pbc25569-cit-0015","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1200\/JCO.2012.43.0132","article-title":"Gemtuzumab ozogamicin: Time to resurrect?","volume":"30","author":"Ravandi","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.25569-BIB0016|pbc25569-cit-0016","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.bbmt.2010.03.016","article-title":"The costs and cost-effectiveness of allogeneic peripheral blood stem cell transplantation versus bone marrow transplantation in patients with acute leukemia","volume":"54","author":"Lin","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1002\/pbc.25569-BIB0017|pbc25569-cit-0017","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/01.mph.0000168724.19025.a4","article-title":"Hospital resource utilization in childhood cancer","volume":"27","author":"Rosenman","year":"2005","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1002\/pbc.25569-BIB0018|pbc25569-cit-0018","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.leukres.2012.09.018","article-title":"The costs of initial treatment for patients with acute myeloid leukemia in the Netherlands","volume":"37","author":"Leunis","year":"2013","journal-title":"Leukemia Res"},{"key":"10.1002\/pbc.25569-BIB0019|pbc25569-cit-0019","doi-asserted-by":"publisher","DOI":"10.1111\/imj.12478","article-title":"Health economic impact of high dose versus standard dose cytarabine induction chemotherapy for acute myeloid leukemia","author":"Fedele","year":"2014","journal-title":"Internal Med"},{"key":"10.1002\/pbc.25569-BIB0020|pbc25569-cit-0020","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1001\/jama.1985.03350400077025","article-title":"The epidemiology of disease expenses","volume":"253","author":"Bloom","year":"1985","journal-title":"JAMA"},{"key":"10.1002\/pbc.25569-BIB0021|pbc25569-cit-0021","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/cncr.10805","article-title":"Financial analysis of patients with newly diagnosed acute myelogenous leukemia on protocol therapy or standard therapy","volume":"95","author":"Berman","year":"2002","journal-title":"Cancer"},{"key":"10.1002\/pbc.25569-BIB0022|pbc25569-cit-0022","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/pbc.22250","article-title":"Costs of pediatric allogeneic hematopoietic-cell transplantation","volume":"54","author":"Majhail","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"10.1002\/pbc.25569-BIB0023|pbc25569-cit-0023","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1600-0609.2009.01397.x","article-title":"Safe and feasible outpatient treatment following induction and consolidation chemotherapy for patients with acute leukemia","volume":"84","author":"M\u00f8ller","year":"2010","journal-title":"Eur J Hematol"},{"key":"10.1002\/pbc.25569-BIB0024|pbc25569-cit-0024","doi-asserted-by":"crossref","first-page":"914","DOI":"10.3324\/haematol.2011.040220","article-title":"Outpatient management following intensive induction chemotherapy for myelodyplastic syndromes and acute myeloid leukemia: A pilot study","volume":"96","author":"Walter","year":"2011","journal-title":"Hematologica"},{"key":"10.1002\/pbc.25569-BIB0025|pbc25569-cit-0025","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/592379","article-title":"Postinduction supportive care of pediatric acute myelocytic leukemia: Should patients be kept in the hospital?","volume":"592379","author":"Inoue","year":"2014","journal-title":"Leukemia Research and Treatment"},{"key":"10.1002\/pbc.25569-BIB0026|pbc25569-cit-0026","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1002\/cncr.28688","article-title":"Feasibility, efficacy, and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia","volume":"120","author":"Inaba","year":"2014","journal-title":"Cancer"},{"key":"10.1002\/pbc.25569-BIB0027|pbc25569-cit-0027","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1200\/JCO.2004.01.078","article-title":"Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection","volume":"22","author":"Santolaya","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.25569-BIB0028|pbc25569-cit-0028","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1542\/peds.2010-0734","article-title":"Cost-effectiveness of outpatient management for febrile neutropenia in children with cancer","volume":"127","author":"Teuffel","year":"2011","journal-title":"Pediatrics"},{"key":"10.1002\/pbc.25569-BIB0029|pbc25569-cit-0029","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1200\/JCO.2011.35.1247","article-title":"Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial","volume":"29","author":"Hendricks","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.25569-BIB0030|pbc25569-cit-0030","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1542\/peds.95.6.896","article-title":"A prospective, controlled evaluation of home chemotherapy for children with cancer","volume":"95","author":"Close","year":"1995","journal-title":"Pediatrics"},{"key":"10.1002\/pbc.25569-BIB0031|pbc25569-cit-0031","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/pbc.20598","article-title":"Hospital and home chemotherapy for children with leukemia: A randomized cross-over study","volume":"47","author":"Stevens","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"10.1002\/pbc.25569-BIB0032|pbc25569-cit-0032","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1182\/blood-2005-10-4004","article-title":"Ethnicity and survival in childhood acute myeloid leukemia: A report from the Children's Oncology Group","volume":"108","author":"Aplenc","year":"2006","journal-title":"Blood"},{"key":"10.1002\/pbc.25569-BIB0033|pbc25569-cit-0033","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/cncr.28617","article-title":"Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period","volume":"120","author":"Aizer","year":"2014","journal-title":"Cancer"},{"key":"10.1002\/pbc.25569-BIB0034|pbc25569-cit-0034","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1158\/1055-9965.EPI-11-0246","article-title":"Sex disparities in cancer mortality and survival","volume":"20","author":"Cook","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1002\/pbc.25569-BIB0035|pbc25569-cit-0035","doi-asserted-by":"publisher","first-page":"e52457","DOI":"10.1371\/journal.pone.0052457","article-title":"Do female cancer patients display better survival rates compared to males? Analysis of the Korean National Registry data, 2005-2009","volume":"7","author":"Jung","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1002\/pbc.25569-BIB0036|pbc25569-cit-0036","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/cam4.84","article-title":"Cancer survival disparities by health insurance status","volume":"2","author":"Niu","year":"2013","journal-title":"Cancer Med"},{"key":"10.1002\/pbc.25569-BIB0037|pbc25569-cit-0037","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/CA.2007.0011","article-title":"Association of insurance with cancer care utilization and outcomes","volume":"58","author":"Ward","year":"2008","journal-title":"CA Cancer J Clin"},{"key":"10.1002\/pbc.25569-BIB0038|pbc25569-cit-0038","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1053\/spsu.2002.29367","article-title":"Using a pediatric database to drive quality improvement","volume":"11","author":"Kittle","year":"2002","journal-title":"Semin Pediatr Surg"},{"key":"10.1002\/pbc.25569-BIB0039|pbc25569-cit-0039","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1023\/A:1008318930947","article-title":"Economic analysis of a randomized placebo-controlled phase III study of granulocyte macrophage colony stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia","volume":"10","author":"Bennett","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1002\/pbc.25569-BIB0040|pbc25569-cit-0040","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/(SICI)1096-911X(200002)34:2<92::AID-MPO3>3.0.CO;2-Q","article-title":"Cost analysis of filgrastim for the prevention of neutropenia in pediatric T-Cell leukemia and advanced lymphoblastic lymphoma: A case for prospective economic analysis in cooperative group trials","volume":"34","author":"Bennett","year":"2000","journal-title":"Med Pediatr Oncol"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.25569","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.25569","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/pbc.25569\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,7]],"date-time":"2022-05-07T10:13:38Z","timestamp":1651918418000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.25569"}},"subtitle":["Inpatient Cost of Pediatric AML Treatment"],"short-title":[],"issued":{"date-parts":[[2015,5,6]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"URL":"https:\/\/doi.org\/10.1002\/pbc.25569","archive":["Portico"],"relation":{},"ISSN":["1545-5009"],"issn-type":[{"value":"1545-5009","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5,6]]}}}